|
|
|
|
|
|
Sponsors and Collaborators: |
Masonic Cancer Center, University of Minnesota National Cancer Institute (NCI) |
Information provided by: | National Cancer Institute (NCI) |
ClinicalTrials.gov Identifier: | NCT00290628 |
RATIONALE: Giving chemotherapy and total-body irradiation before a donor umbilical cord blood transplant helps stop the growth of cancer and abnormal cells and helps stop the patient's immune system from rejecting the donor's stem cells. When the stem cells from a related or unrelated donor, that do not exactly match the patient's blood, are infused into the patient they may help the patient's bone marrow to make stem cells, red blood cells, white blood cells, and platelets.
PURPOSE: This clinical trial is studying how well donor umbilical cord blood transplant works in treating patients with hematologic cancer.
Condition | Intervention |
Chronic Myeloproliferative Disorders Diamond-Blackfan Anemia Fanconi Anemia Graft Versus Host Disease Leukemia Lymphoma Multiple Myeloma and Plasma Cell Neoplasm Myelodysplastic Syndromes Myelodysplastic/Myeloproliferative Diseases |
Drug: anti-thymocyte globulin Drug: busulfan Drug: cyclophosphamide Drug: cyclosporine Drug: filgrastim Drug: melphalan Drug: methylprednisolone Drug: mycophenolate mofetil Procedure: radiation therapy Procedure: umbilical cord blood transplantation |
Genetics Home Reference related topics: | aceruloplasminemia hemophilia |
MedlinePlus related topics: | Anemia Cancer Hodgkin's Disease Leukemia, Adult Acute Leukemia, Adult Chronic Leukemia, Childhood Lymphoma Multiple Myeloma |
Study Type: | Interventional |
Study Design: | Treatment, Open Label |
Official Title: | Transplantation of Umbilical Cord Blood From Related and Unrelated Donors |
Ages Eligible for Study: | up to 45 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
Diagnosis of 1 of the following:
Leukemia including, but not limited to, the following subtypes:
HLA-identical or 1, 2, or 3 antigen mismatched umbilical cord blood (UCB) donor with at least one DRB1 match available
PATIENT CHARACTERISTICS:
PRIOR CONCURRENT THERAPY:
United States, Minnesota | |||||
University of Minnesota Cancer Center | |||||
Minneapolis, Minnesota, United States, 55455 |
Masonic Cancer Center, University of Minnesota |
National Cancer Institute (NCI) |
Study Chair: | John E. Wagner, MD | Masonic Cancer Center, University of Minnesota |
Clinical trial summary from the National Cancer Institute's PDQ® database 
  |
Study ID Numbers: | CDR0000450845, UMN-2000LS017, UMN-MT1999-28 |
First Received: | February 9, 2006 |
Last Updated: | July 23, 2008 |
ClinicalTrials.gov Identifier: | NCT00290628 |
Health Authority: | United States: Federal Government |
|
|
|
|
|
|